# Creative Medical Technology Holdings Inc. (CELZ)

Source: https://www.quantisnow.com/company/CELZ
Generated: 2026-11-18T12:51:23.116Z

- Ticker: CELZ
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- SEC CIK: 0001187953
- Website: https://www.creativemedicaltechnology.com

## About

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.

## Latest CELZ news and filings

- 2026-11-13 21:05 UTC [SEC Form 8-K] [Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-filed-sec-form-8-k-notice-6790510)
- 2026-11-10 21:06 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-creative-medical-technology-holdings-6783957)
- 2026-11-06 21:45 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-creative-medical-technology-holdings-inc-6779364)
- 2026-10-20 13:15 UTC [Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study](https://www.quantisnow.com/insight/creative-medical-technology-holdings-highlights-93-patient-response-rate-and-6751789)
- 2026-09-25 22:00 UTC [SEC Form 4] [President & CEO Warbington Timothy was granted 1,000,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-warbington-timothy-was-granted-1000000-shares-sec-form-6726800)
- 2026-09-25 21:00 UTC [SEC Form 8-K] [Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-filed-sec-form-8-k-entry-6726701)
- 2026-09-17 13:00 UTC [Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-expands-ultrasome-intellectual-property-portfolio-6718627)
- 2026-08-31 20:05 UTC [SEC Form 8-K] [Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-filed-sec-form-8-k-amendments-6699717)
- 2026-08-20 13:15 UTC [Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning](https://www.quantisnow.com/insight/creative-medical-technology-holdings-successfully-completes-enrollment-and-treatment-across-6689693)
- 2026-08-07 21:23 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-creative-medical-technology-holdings-inc-6672155)
- 2026-08-06 13:15 UTC [Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-receives-notice-of-allowance-for-6667839)
- 2026-08-03 20:05 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-creative-medical-technology-holdings-inc-6659662)
- 2026-08-03 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-creative-medical-technology-holdings-inc-6658480)
- 2026-07-24 20:05 UTC [SEC Form S-3] [SEC Form S-3 filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-creative-medical-technology-holdings-inc-6648299)
- 2026-07-14 20:00 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-creative-medical-technology-holdings-6636648)
- 2026-07-02 20:15 UTC [SEC Form 8-K] [Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-filed-sec-form-8-k-entry-6625441)
- 2026-07-01 20:05 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-creative-medical-technology-holdings-6622826)
- 2026-07-01 13:00 UTC [Creative Medical Technology Holdings Issues Mid-Year Update](https://www.quantisnow.com/insight/creative-medical-technology-holdings-issues-mid-year-update-6622131)
- 2026-06-30 18:07 UTC [Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds](https://www.quantisnow.com/insight/creative-medical-technology-holdings-announces-agreements-for-exercise-of-warrants-6620581)
- 2026-06-30 12:30 UTC [SEC Form RW filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-rw-filed-by-creative-medical-technology-holdings-inc-6620167)
- 2026-06-26 20:16 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-creative-medical-technology-holdings-6617403)
- 2026-06-25 20:06 UTC [SEC Form S-1] [SEC Form S-1 filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-creative-medical-technology-holdings-inc-6615760)
- 2026-06-22 13:15 UTC [Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain](https://www.quantisnow.com/insight/creative-medical-technology-holdings-expands-adapt-trial-under-new-fda-6610301)
- 2026-06-16 13:00 UTC [Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-advances-project-phoenix-into-nationwide-6604132)
- 2026-05-08 20:45 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-creative-medical-technology-holdings-inc-6542690)
- 2026-04-28 13:01 UTC [Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-reports-breakthrough-93-response-rate-6517974)
- 2026-04-24 20:45 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-creative-medical-technology-holdings-6514865)
- 2026-03-20 20:45 UTC [SEC Form 10-K] [SEC Form 10-K filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-creative-medical-technology-holdings-inc-6463532)
- 2026-02-10 14:00 UTC [Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline](https://www.quantisnow.com/insight/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-6383291)
- 2026-01-13 14:15 UTC [Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain](https://www.quantisnow.com/insight/creative-medical-technology-holdings-reaches-major-clinical-inflection-point-with-6347704)
- 2026-01-06 14:15 UTC [Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative](https://www.quantisnow.com/insight/creative-medical-technology-holdings-receives-regulatory-approval-for-biodefense-burn-6337634)
- 2025-12-31 21:05 UTC [SEC Form 8-K] [Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-filed-sec-form-8-k-submission-6330870)
- 2025-12-19 21:01 UTC [SEC Form 8-K] [Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-filed-sec-form-8-k-submission-6323604)
- 2025-12-17 14:15 UTC [Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-completes-enrollment-in-fda-cleared-adapt-6319347)
- 2025-12-16 21:05 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-creative-medical-technology-holdings-inc-6317910)
- 2025-12-15 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-creative-medical-technology-holdings-inc-6315121)
- 2025-12-02 14:15 UTC [Creative Medical Technology Holdings Announces World Health Organization Approval of "olastrocel" as INN for Lead Allogeneic Cell Therapy CELZ-201](https://www.quantisnow.com/insight/creative-medical-technology-holdings-announces-world-health-organization-approval-of-6299143)
- 2025-11-21 21:31 UTC [SEC Form S-3] [SEC Form S-3 filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-creative-medical-technology-holdings-inc-6290426)
- 2025-11-13 21:51 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Creative Medical Technology Holdings Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-creative-medical-technology-holdings-6278073)
- 2025-11-12 11:12 UTC [SEC Form 8-K] [Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/creative-medical-technology-holdings-inc-filed-sec-form-8-k-leadership-6272447)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CELZ
- Earnings history: https://www.quantisnow.com/earnings/CELZ
- Dividend history: https://www.quantisnow.com/dividends/CELZ
- Insider transactions: https://www.quantisnow.com/insiders/CELZ
- Options chain: https://www.quantisnow.com/options/CELZ
- SEC 8-K filings only: https://www.quantisnow.com/company/CELZ/8-k
- RSS and alerts for CELZ: https://www.quantisnow.com/docs/rss-feeds.md
